The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading ->
A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading ->
Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading ->
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading ->
Clemens Martin Auer, director general of Austria’s Ministry of Health, could be said to take a pragmatic and original perspective when it comes to European and national policy. In an interview with Health Policy Watch during the recent European Health Forum in Bad Gastein, Austria, he discussed health priorities for the current Austrian presidency of the European Union and beyond. He also discussed ongoing efforts by a number of European countries to address high prices of medicines and public funding for R&D. This is the second of two parts. Continue reading ->
Dorli Kahr-Gottlieb writes: For more than 20 years, every October, around 500 leading health experts from governmental institutions, civil society, the academic world, and the private sector meet up at the European Health Forum Gastein (EHFG). They meet to discuss Europe’s contemporary health challenges and address pressing issues around the sustainability of European health systems in a Davos like setting, in the presence of Ministers of Health and senior European Commission and WHO officials. This year’s edition of the EHFG, called simply “Gastein” by the cognoscente, is an official Austrian EU Presidency event. Over the three days, Gastein is not going to shy away from the big European political debates such as how much of a role Europe should play in shaping health policy; but also it is going to take on some of the big global health policy challenges. Continue reading ->